FLT3 and acute lymphoblastic leukemia: Encouragingly, a report indicated that, following HSCT relapse and the detection of a FLT3-TKD mutation, an early T-cell precursor ALL patient achieved a second complete remission and MRD negativity with gilteritinib treatment [43].